Amedisys (AMED) Misses Q4 EPS by 2c, Offers Guidance

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.56, $0.02 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $404.2 million versus the consensus estimate of $394.62 million.

GUIDANCE:

Amedisys sees FY2018 EPS of $2.97-$3.08, may not compare to the consensus of $2.66. Amedisys sees FY2018 revenue of $1.6-1.64 billion, versus the consensus of $1.63 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance